Highlights Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
43.08 ^USD	-1.69%		-4.20%	+16.56%

May. 22	Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing	MT
May. 07	Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	May. 07	MT
(HALO) HALOZYME THERAPEUTICS Sees Fiscal Year 2024 Revenue Range $915M - $985M	May. 07	MT
Earnings Flash (HALO) HALOZYME THERAPEUTICS Posts Q1 Revenue $195.9M, vs. Street Est of $199.7M	May. 07	MT
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q1 EPS $0.79, vs. Street Est of $0.70	May. 07	MT
Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on February 20, 2024.	May. 07	CI
Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021.	May. 07	CI
Halozyme Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024	May. 07	CI
Halozyme Therapeutics Q4 Adjusted Earnings, Revenue Rise; Reiterates 2024 Guidance	Feb. 21	MT
Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on December 9, 2021.	Feb. 20	CI
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 EPS $0.82, vs. Street Est of $0.83	Feb. 20	MT
(HALO) HALOZYME THERAPEUTICS Forecasts Fiscal Year 2024 Revenue Range $915M - $985M	Feb. 20	MT
Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q4 Revenue $230M, vs. Street Est of $231.1M	Feb. 20	MT
Halozyme Therapeutics Guides For 2024 EPS of $3.55-$3.90, vs CIQ Analyst Consensus of $3.64/Share	Feb. 20	MT
Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 20	CI
Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares.	Feb. 20	CI
Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 20	CI
Halozyme Therapeutics, Inc. authorizes a Buyback Plan.	Jan. 31	CI
Halozyme Announces Takeda Receives European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy	Jan. 29	CI
Halozyme Therapeutics Says Argenx Gets Japan's Approval for Vyvdura to Treat Certain Generalized Myasthenia Gravis Patients	Jan. 18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Highlights

Filters